BRIEF-AstraZeneca Says Its Antibody Treatment Failed In Preventing COVID-19 In Exposed Patients

AstraZeneca PLC: * ASTRAZENECA PLC - UPDATE ON AZD7442 STORM CHASER TRIAL

* ASTRAZENECA PLC - UPDATE ON AZD7442 STORM CHASER TRIAL * ASTRAZENECA - TRIAL DID NOT MEET PRIMARY ENDPOINT OF POST-EXPOSURE PREVENTION OF SYMPTOMATIC COVID-19 WITH AZD7442 COMPARED TO PLACEBO.

* ASTRAZENECA - IN OVERALL TRIAL POPULATION, AZD7442 REDUCED RISK OF DEVELOPING SYMPTOMATIC COVID-19 BY 33% (95% CONFIDENCE INTERVAL (CI): -26, 65) COMPARED TO PLACEBO * ASTRAZENECA - TRIAL INCLUDED 1,121 PARTICIPANTS IN A 2:1 RANDOMISATION AZD7442 TO PLACEBO

* ASTRAZENECA - IN POSTHOC ANALYSIS, IN PARTICIPANTS WHO WERE PCR NEGATIVE AT BASELINE, AZD7442 REDUCED RISK OF DEVELOPING SYMPTOMATIC COVID-19 BY 92% * ASTRAZENECA - IN A PRE-PLANNED ANALYSIS OF SARS-COV-2 PCR POSITIV AND PCR NEGATIVE PARTICIPANTS, AZD7442 REDUCED RISK OF DEVELOPING SYMPTOMATIC COVID-19 BY 73% COMPARED WITH PLACEBO

* ASTRAZENECA - AZD7442 WAS WELL TOLERATED IN TRIAL. * ASTRAZENECA - PRELIMINARY ANALYSES SHOW SIMILAR ADVERSE EVENTS IN PLACEBO AND TREATMENT ARMS. 

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)